S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Viatris Stock Forecast, Price & News

+0.23 (+2.14%)
(As of 06/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
11.83 million shs
Average Volume
12.67 million shs
Market Capitalization
$13.29 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive VTRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viatris and its competitors with MarketBeat's FREE daily newsletter.

VTRS Stock Forecast (MarketRank)

Overall MarketRank

2.45 out of 5 stars

Medical Sector

164th out of 1,411 stocks

Pharmaceutical Preparations Industry

60th out of 672 stocks

Analyst Opinion: 1.8Community Rank: 3.6Dividend Strength: 2.5Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
Viatris logo

About Viatris (NASDAQ:VTRS)

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

VTRS Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Ex-Dividend for 6/16 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$-1.27 billion
Pretax Margin


Sales & Book Value

Annual Sales
$17.89 billion
Cash Flow
$7.41 per share
Book Value
$16.94 per share


Outstanding Shares
Free Float
Market Cap
$13.29 billion
Not Optionable

Viatris Frequently Asked Questions

Should I buy or sell Viatris stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viatris in the last twelve months. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Viatris stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTRS, but not buy additional shares or sell existing shares.
View analyst ratings for Viatris
or view top-rated stocks.

What is Viatris' stock price forecast for 2022?

5 analysts have issued 1-year target prices for Viatris' stock. Their VTRS stock forecasts range from $9.00 to $19.00. On average, they expect Viatris' share price to reach $12.40 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price.
View analysts' price targets for Viatris
or view top-rated stocks among Wall Street analysts.

How has Viatris' stock performed in 2022?

Viatris' stock was trading at $13.53 at the beginning of 2022. Since then, VTRS shares have decreased by 19.0% and is now trading at $10.96.
View the best growth stocks for 2022 here

When is Viatris' next earnings date?

Viatris is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Viatris

How were Viatris' earnings last quarter?

Viatris Inc. (NASDAQ:VTRS) released its quarterly earnings results on Monday, May, 9th. The company reported $0.33 earnings per share for the quarter, missing analysts' consensus estimates of $0.83 by $0.50. The business had revenue of $4.19 billion for the quarter, compared to analysts' expectations of $4.26 billion. Viatris had a net margin of 0.95% and a trailing twelve-month return on equity of 21.50%. The firm's revenue for the quarter was down 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.92 EPS.
View Viatris' earnings history

How often does Viatris pay dividends? What is the dividend yield for Viatris?

Viatris announced a quarterly dividend on Monday, May 9th. Shareholders of record on Tuesday, May 24th will be paid a dividend of $0.12 per share on Thursday, June 16th. This represents a $0.48 annualized dividend and a dividend yield of 4.38%. The ex-dividend date is Monday, May 23rd.
View Viatris' dividend history

Is Viatris a good dividend stock?

Viatris(NASDAQ:VTRS) pays an annual dividend of $0.48 per share and currently has a dividend yield of 4.38%. VTRS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of Viatris is 342.86%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Viatris will have a dividend payout ratio of 14.16% next year. This indicates that Viatris will be able to sustain or increase its dividend.
View Viatris' dividend history.

How will Viatris' stock buyback program work?

Viatris declared that its board has authorized a share buyback plan on Monday, February 28th 2022, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 7.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its shares are undervalued.

What guidance has Viatris issued on next quarter's earnings?

Viatris updated its FY 2022 earnings guidance on Monday, June, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $17.00 billion-$17.50 billion, compared to the consensus revenue estimate of $17.24 billion.

Who are Viatris' key executives?

Viatris' management team includes the following people:
  • Mr. Robert J. Coury, Exec. Chairman (Age 61, Pay $7.75M)
  • Mr. Michael Goettler, CEO & Exec. Director (Age 54, Pay $5.57M) (LinkedIn Profile)
  • Mr. Rajiv Malik, Pres & Exec. Director (Age 61, Pay $4.42M)
  • Mr. Sanjeev Narula, Chief Financial Officer (Age 61, Pay $2.85M)
  • Mr. Anthony Mauro, Pres of Developed Markets (Age 49, Pay $2.85M)
  • Mr. Sanjeev Kumar Sethi, Chief Operating Officer (Age 55)
  • Mr. Paul B. Campbell, Chief Accounting Officer, Sr. VP & Corp. Controller (Age 55)
  • Mr. Ramkumar Rayapureddy, Chief Information Officer
  • Ms. Melissa Trombetta, Head of Global Investor Relations
  • Mr. Brian S. Roman, Global Gen. Counsel (Age 52)

What is Michael Goettler's approval rating as Viatris' CEO?

8 employees have rated Viatris CEO Michael Goettler on Glassdoor.com. Michael Goettler has an approval rating of 85% among Viatris' employees.

What is Viatris' stock symbol?

Viatris trades on the NASDAQ under the ticker symbol "VTRS."

Who are Viatris' major shareholders?

Viatris' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.41%), BlackRock Inc. (7.28%), State Street Corp (4.67%), Deerfield Management Company L.P. Series C (1.71%), Invesco Ltd. (1.23%) and Northern Trust Corp (1.02%). Company insiders that own Viatris stock include James M Kilts, Menassie Taddese, Michael Goettler, Robert J Coury and W Don Cornwell.
View institutional ownership trends for Viatris

Which institutional investors are selling Viatris stock?

VTRS stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Bank of Montreal Can, Bank of New York Mellon Corp, National Pension Service, Monaco Asset Management SAM, Sumitomo Mitsui Trust Holdings Inc., US Bancorp DE, and UBS Group AG. Company insiders that have sold Viatris company stock in the last two years include Menassie Taddese, and Robert J Coury.
View insider buying and selling activity for Viatris
or view top insider-selling stocks.

Which institutional investors are buying Viatris stock?

VTRS stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Pacer Advisors Inc., State Street Corp, Arrowstreet Capital Limited Partnership, Invesco Ltd., Bank of Nova Scotia, BlackRock Inc., and Renaissance Technologies LLC. Company insiders that have bought Viatris stock in the last two years include James M Kilts, Michael Goettler, and W Don Cornwell.
View insider buying and selling activity for Viatris
or or view top insider-buying stocks.

How do I buy shares of Viatris?

Shares of VTRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viatris' stock price today?

One share of VTRS stock can currently be purchased for approximately $10.96.

How much money does Viatris make?

Viatris (NASDAQ:VTRS) has a market capitalization of $13.29 billion and generates $17.89 billion in revenue each year. The company earns $-1.27 billion in net income (profit) each year or $0.14 on an earnings per share basis.

How many employees does Viatris have?

Viatris employs 37,000 workers across the globe.

How can I contact Viatris?

Viatris' mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The official website for Viatris is www.viatris.com. The company can be reached via phone at (724) 514-1800, via email at [email protected], or via fax at 724-514-1870.

This page (NASDAQ:VTRS) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.